4 completed, 3 unknown, 1 recruiting, 1 withdrawn. 5 Phase 2, 4 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Unknown 2, Recruiting 1 |
| Not applicable | 4 | Completed 2, Unknown 1, Withdrawn 1 |
| Phase 1 | 1 | Unknown 1 |
Follow Nausea Post Chemotherapy: new trials by email Literature Review of Nausea Post Chemotherapy trials Research Report on Nausea Post Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TRANSCUTANEOUS ELECTRICAL ACUPOINT STIMULATION FOR CISPLATIN- CHEMOTHERAPY INDUCED NAUSEA AND VOMITING Transcutaneous electrical nerve stimulation, Antiemetic - Nausea Post Chemotherapy, Vomiting | Not applicable | Completed | Cairo University | 34 | 2025-10-15 | 2026-04-03 |
| Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC) IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion - Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy | Phase 2 | Recruiting | Helsinn Healthcare SA | 95 | 2025-07-07 | 2026-09-29 |
| Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC Pharmacokinetic and pharmacodynamic profile of THC oral formulations with Dronabinol as comparator - Nausea Post Chemotherapy, Vomiting | Phase 1 / Phase 2 | Unknown | LaSanta S A S | 334 | 2023-08-15 | 2023-02-01 |
| Effects of Short-term Therapeutic Fasting on Nausea and Vomiting Due to Chemotherapy therapeutic fasting - Nausea Post Chemotherapy, Vomiting | Not applicable | Unknown | Centre Hospitalier Universitaire de la Réunion | 30 | 2022-01-20 | 2023-10-31 |
| Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer Olanzapine, Netupitant, Palonesetron - Nausea Post Chemotherapy | Phase 2 | Completed | Instituto Brasileiro de Controle do Cancer | 50 | 2020-12-17 | 2022-02-23 |
| Prevention of Unmitigated Chemotherapy-induced Emesis Otoband, Placebo device - Chemotherapy-induced Nausea and Vomiting, Nausea Post Chemotherapy | Not applicable | Withdrawn | Otolith Labs | 2019-08-01 | 2021-04-27 | |
| Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis Olanzapine, Aprepitant Pill, Ondansetron - Emesis, Vomiting | Phase 2 | Unknown | Blokhin's Russian Cancer Research Center | 130 | 2018-05-25 | 2018-07-05 |
| Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC Aprepitant - Vomiting, Nausea Post Chemotherapy | Phase 2 | Completed | Chinese Academy of Medical Sciences | 44 | 2018-03-01 | 2020-07-15 |
| Fosaprepitant Dimeglumine in Preventing Nausea and Vomiting in Patients With Gastrointestinal Cancer Receiving Combination Chemotherapy fosaprepitant dimeglumine - Gastrointestinal Cancer, Nausea Post Chemotherapy | Not applicable | Completed | Philip Philip | 30 | 2012-06-01 | 2021-04-08 |
Vomiting (7) · Nausea (4) · Breast Neoplasms (1) · Cancer Pain (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Neoplasms (1)
Pathological Conditions, Signs and Symptoms (8) · Signs and Symptoms (8) · Signs and Symptoms, Digestive (8) · Neoplasms (3) · Neoplasms by Site (3) · Breast Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Neurologic Manifestations (1) · Pain (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
Aprepitant (3) · Dexamethasone (2) · Olanzapine (2) · Ondansetron (2) · Antiemetics (1) · Dronabinol (1) · Palonosetron (1) · Transcutaneous Electric Nerve Stimulation (1) · fosaprepitant (1) · netupitant (1)
Blokhin's Russian Cancer Research Center (1) · Cairo University (1) · Centre Hospitalier Universitaire de la Réunion (1) · Chinese Academy of Medical Sciences (1) · Helsinn Healthcare SA (1) · Instituto Brasileiro de Controle do Cancer (1) · LaSanta S A S (1) · Otolith Labs (1) · Philip Philip (1)
United States (2) · Brazil (1) · China (1) · Colombia (1) · Egypt (1) · France (1) · Greece (1) · Poland (1) · Romania (1) · Russia (1) · Turkey (Türkiye) (1)
Junlin Yi, M.D. (1) · Michael S Sherman, MD (1) · Philip A. Philip, M.D., Ph.D., F.R.C.P (1)
P30CA022453 (1)